Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

1.

Human bone marrow stromal cells differentiate into corneal tissue and prevent ocular graft-versus-host disease in mice.

Sánchez-Abarca LI, Hernández-Galilea E, Lorenzo R, Herrero C, Velasco A, Carrancio S, Caballero-Velázquez T, Rodríguez-Barbosa JI, Parrilla M, Cañizo CD, Miguel JS, Aijón J, Pérez-Simón JA.

Cell Transplant. 2015 Feb 18. [Epub ahead of print]

PMID:
25695936
2.

Transcriptomic portrait of human Mesenchymal Stromal/Stem cells isolated from bone marrow and placenta.

Roson-Burgo B, Sanchez-Guijo F, Del Cañizo C, De Las Rivas J.

BMC Genomics. 2014 Oct 19;15:910. doi: 10.1186/1471-2164-15-910.

3.

NADPH oxidases as therapeutic targets in chronic myelogenous leukemia.

Sánchez-Sánchez B, Gutiérrez-Herrero S, López-Ruano G, Prieto-Bermejo R, Romo-González M, Llanillo M, Pandiella A, Guerrero C, Miguel JF, Sánchez-Guijo F, Del Cañizo C, Hernández-Hernández A.

Clin Cancer Res. 2014 Aug 1;20(15):4014-25. doi: 10.1158/1078-0432.CCR-13-3044. Epub 2014 May 15.

PMID:
24833663
4.

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.

Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, Selleslag D, Beyne-Rauzy O, te Boekhorst P, del Cañizo C, Guerci-Bresler A, Nilsson L, Lübbert M, Quesnel B, Ganser A, Bowen D, Schlegelberger B, Göhring G, Fu T, Benettaib B, Hellström-Lindberg E, Fenaux P.

Eur J Haematol. 2014 Nov;93(5):429-38. doi: 10.1111/ejh.12380. Epub 2014 Jun 9.

5.

Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease.

Bueno C, Roldan M, Anguita E, Romero-Moya D, Martín-Antonio B, Rosu-Myles M, del Cañizo C, Campos F, García R, Gómez-Casares M, Fuster JL, Jurado M, Delgado M, Menendez P.

Haematologica. 2014 Jul;99(7):1168-75. doi: 10.3324/haematol.2014.103580. Epub 2014 Apr 11.

6.

Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.

Sánchez-García J, Del Cañizo C, Lorenzo I, Nomdedeu B, Luño E, de Paz R, Xicoy B, Valcárcel D, Brunet S, Marco-Betes V, García-Pintos M, Osorio S, Tormo M, Bailén A, Cerveró C, Ramos F, Diez-Campelo M, Such E, Arrizabalaga B, Azaceta G, Bargay J, Arilla MJ, Falantes J, Serrano-López J, Sanz GF; Spanish Group on Myelodysplastic Syndromes (GES MD).

Br J Haematol. 2014 Jul;166(2):189-201. doi: 10.1111/bjh.12876. Epub 2014 Apr 10.

PMID:
24716538
7.

Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.

Bernal T, Diez-Campelo M, Godoy V, Rojas S, Colado E, Alcoceba M, González M, Vidriales B, Sánchez-Guijo FM, López-Corral L, Luño E, del Cañizo C.

Leuk Res. 2014 May;38(5):551-6. doi: 10.1016/j.leukres.2014.02.001. Epub 2014 Feb 10.

PMID:
24655806
8.

Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.

Rojas SM, Díez-Campelo M, Luño E, Cabrero M, Pedro C, Calabuig M, Nomdedeu B, Cedena T, Arrizabalaga B, García M, Cerveró C, Collado R, Azaceta G, Ardanaz MT, Muñoz JA, Xicoy B, Rodríguez MJ, Bargay J, Morell MJ, Simiele A, del Cañizo C.

Leuk Res. 2014 Mar;38(3):304-9. doi: 10.1016/j.leukres.2013.11.005. Epub 2013 Nov 15.

PMID:
24333115
9.

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M; European Leukemia Net.

Blood. 2013 Oct 24;122(17):2943-64. doi: 10.1182/blood-2013-03-492884. Epub 2013 Aug 26.

10.

Uptake and delivery of antigens by mesenchymal stromal cells.

Sánchez-Abarca LI, Alvarez-Laderas I, Díez Campelo M, Caballero-Velázquez T, Herrero C, Muntión S, Calderón C, García-Guerrero E, Sánchez-Guijo F, Del Cañizo C, San Miguel J, Pérez-Simón JA.

Cytotherapy. 2013 Jun;15(6):673-8. doi: 10.1016/j.jcyt.2013.01.216. Epub 2013 Mar 21.

PMID:
23522868
11.

Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome.

Valcárcel D, Ademà V, Solé F, Ortega M, Nomdedeu B, Sanz G, Luño E, Cañizo C, de la Serna J, Ardanaz M, Marco V, Collado R, Grau J, Montoro J, Mallo M, Vallespí T.

J Clin Oncol. 2013 Mar 1;31(7):916-22. doi: 10.1200/JCO.2012.41.6073. Epub 2013 Jan 14.

12.

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U; International Working Group on MDS with del(5q).

Leukemia. 2013 Apr;27(5):1072-9. doi: 10.1038/leu.2012.369. Epub 2012 Dec 21.

13.

Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes.

Saumell S, Florensa L, Luño E, Sanzo C, Cañizo C, Hernández JM, Cervera J, Gallart MA, Carbonell F, Collado R, Arenillas L, Pedro C, Bargay J, Nomdedeu B, Xicoy B, Vallespí T, Raya JM, Belloch L, Sanz GF, Solé F.

Br J Haematol. 2012 Nov;159(3):311-21. doi: 10.1111/bjh.12035. Epub 2012 Sep 7.

PMID:
22958186
14.

Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.

Santamaría C, Ramos F, Puig N, Barragán E, de Paz R, Pedro C, Insunza A, Tormo M, Del Cañizo C, Diez-Campelo M, Xicoy B, Salido E, Sánchez del Real J, Hernández M, Chillón C, Sanz GF, García-Sanz R, San Miguel JF, González M.

Ann Hematol. 2012 Dec;91(12):1887-95. doi: 10.1007/s00277-012-1538-7. Epub 2012 Aug 9.

PMID:
22875062
15.

The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.

Caballero-Velázquez T, Sánchez-Abarca LI, Gutierrez-Cosio S, Blanco B, Calderon C, Herrero C, Carrancio S, Serrano C, del Cañizo C, San Miguel JF, Pérez-Simón JA.

Haematologica. 2012 Sep;97(9):1329-37. doi: 10.3324/haematol.2011.058677. Epub 2012 Apr 24.

16.

Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment.

Gutierrez-Cosío S, de la Rica L, Ballestar E, Santamaría C, Sánchez-Abarca LI, Caballero-Velazquez T, Blanco B, Calderón C, Herrero-Sánchez C, Carrancio S, Ciudad L, Cañizo C, San Miguel JF, Pérez-Simón JA.

Leuk Res. 2012 Jul;36(7):895-9. doi: 10.1016/j.leukres.2012.02.030. Epub 2012 Apr 13.

PMID:
22503131
17.

[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations].

López Arrieta JM, De Paz R, Altés A, del Cañizo C; Sociedad Española de Medicina Geriátrica; Sociedad Española de Hematología y Hemoterapia.

Med Clin (Barc). 2012 Feb 18;138(3):119.e1-9. doi: 10.1016/j.medcli.2011.08.003. Epub 2011 Oct 26. Spanish.

PMID:
22032819
18.

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E; MDS-004 Lenalidomide del5q Study Group.

Blood. 2011 Oct 6;118(14):3765-76. doi: 10.1182/blood-2011-01-330126. Epub 2011 Jul 13.

19.

Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome.

Cordoba I, González-Porras JR, Nomdedeu B, Luño E, de Paz R, Such E, Tormo M, Vallespi T, Collado R, Xicoy B, Andreu R, Muñoz JA, Solé F, Cervera J, del Cañizo C; Spanish Myelodysplastic Syndrome Registry.

Cancer. 2012 Jan 1;118(1):127-33. doi: 10.1002/cncr.26279. Epub 2011 Jun 29.

20.

Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial.

Pérez-Simon JA, López-Villar O, Andreu EJ, Rifón J, Muntion S, Diez Campelo M, Sánchez-Guijo FM, Martinez C, Valcarcel D, Cañizo CD.

Haematologica. 2011 Jul;96(7):1072-6. doi: 10.3324/haematol.2010.038356. Epub 2011 Mar 10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk